New Weill Cornell Study: Thalidomide and Lenalidomide + Rituximab (ThRiL) for Previously Treated Waldenstrom Macroglobulinemia

A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients with Previously Treated Waldenstrom Macroglobulinemia

Update: this study is closed to enrollment. 

The Weill Cornell Lymphoma Program is now enrolling patients in a newly opened, investigator-initiated clinical trial for people with previously treated Waldenstrom Macroglobulinemia. The principal investigator is Peter Martin, MD.

For more information about the study, please call Amelyn Rodriguez, RN at (212) 746-1362 or email Amelyn at amr2017@med.cornell.edu.

Key eligibility

  • Previously treated for Waldenstrom Macroglobulinemia
  • Not currently treated with other anti-cancer agents or treatments
  • No prior treatment with thalidomide or lenalidomide
  • Detailed eligibility reviewed when you contact the study team

Study Details

The study is evaluating the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in people with previously treated Waldenstrom Macroglobulunemia (WM).

Thalidomide and lenalidomide are drugs that modulate the immune system and have been shown to bring about responses in patients with WM. However, their use has been limited due to side effects. Alternating doses of thalidomide and lenalidomide may alleviate the side effects while preserving the effectiveness of the therapies.

Treatment Plan

  • Thalidomide every ODD day of a 28 day cycle
  • Lenalidomide every EVEN day of a 28 day cycle
  • Rituximab on Days 1, 8, 15 and 22 and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycles 7, 13, 19, etc)

Study participants may continue to receive thalidomide and lenalidomide until their disease worsens.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s